The clonoSEQ® Watch Registry

Verified

Overview

This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.

SparkCures ID 1097
Trial Phase Observational Trial
Enrollment 528 Patients
Tags
Trial Sponsors
  • Adaptive Biotechnologies
NCT Identifier

NCT04545333

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

Inclusion Criteria:

  1. Patients must be able to provide written informed consent
  2. A decision has been made by the treating provider to use the clonoSEQ Assay as part of routine clinical care
  3. Age ≥ 18 years;
  4. Documented hematologic malignancy (any of the below):
    1. MM
    2. ALL (B and T-cell subtypes)
    3. B-cell NHL (all sub types)
    4. CLL
    5. Other lymphoid malignancies (upon review and approval by study chair)

Exclusion Criteria:

Patients must not meet any of the following criteria in order to be enrolled into the study:

  1. Concurrent enrollment in a clinical trial where treatment decisions and patterns are dictated per protocol
  2. A decision has been made by the treating provider to not use the clonoSEQ Assay as part of routine clinical care

The following criteria is provided for health care professionals.

Inclusion Criteria:

  1. Patients must be able to provide written informed consent
  2. A decision has been made by the treating provider to use the clonoSEQ Assay as part of routine clinical care
  3. Age ≥ 18 years;
  4. Documented hematologic malignancy (any of the below):
    1. MM
    2. ALL (B and T-cell subtypes)
    3. B-cell NHL (all sub types)
    4. CLL
    5. Other lymphoid malignancies (upon review and approval by study chair)

Exclusion Criteria:

Patients must not meet any of the following criteria in order to be enrolled into the study:

  1. Concurrent enrollment in a clinical trial where treatment decisions and patterns are dictated per protocol
  2. A decision has been made by the treating provider to not use the clonoSEQ Assay as part of routine clinical care

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Not Currently Accepting Patients

The following is a listing of trial locations that are not currently open and accepting patients.

Hematology Oncology Clinic
Hematology Oncology Clinic

Baton Rouge, LA

California
Stanford Cancer Institute
Colorado
University of Colorado Cancer Center Anschutz Cancer Pavilion
Florida
Holy Cross Hospital Holy Cross Health, A Member of Trinity Health
Louisiana
Hematology Oncology Clinic
Hematology Oncology Clinic

Baton Rouge, LA

Maryland
Missouri
North Carolina
Presbyterian Hospital Novant Health
Oregon
Pennsylvania
Abramson Cancer Center University of Pennsylvania
South Carolina
Bon Secours St. Francis Hospital (Downtown)
Washington
Washington, D.C.
MedStar Georgetown University Hospital

Resources

There are no resources, links or videos to display for this clinical trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Adaptive Biotechnologies to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors